drugset / Trial / NCT05190705
Loncastuximab Tesirine in WM
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Timeline
- Start
- 2022-02-17
- Primary completion
- 2026-05-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loncastuximab Tesirine | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |